Company intelligence / Profile preview

Alexar Therapeutics

Wayne, Pennsylvania, United Statesalextherapeutics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Alexar Therapeutics is developing topical and systemic therapies based on Liver X Receptor modulators. Its lead compound, ALX‑101/A‑110, is a topical LXR agonist for inflammatory skin diseases such as atopic dermatitis. The company has also received funding to explore applications in neurodegenerative diseases like Parkinson’s disease. Clinical results have not been published publicly.

Therapeutic areas: DermatologyNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

Almee

Commercial

Indications: Anxiety, Pulmonary fibrosis

Partnerships

No major pharma partnerships disclosed; initial investors include New Science Ventures and Third Point Ventures.Received Michael J. Fox Foundation grant for PD research.

Beyond the preview

Go deeper on Alexar Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alexar Therapeutics.

Explore the full profile